Determinants of Protection by Human Immune Globulin against Experimental Herpes Neonatorum

Abstract

There is no established prophylaxis of Herpes neonatorurn. In experimental, newborn animals protection can be achieved by sufficient passive antibody given shortly after infection. Animal model data was sought to estimate a realistic and practical dose of human immune globulin for prophylaxis of newborn humans at risk. We used a neonatal mouse model and type I1 herpes simplex virus (HSV) to evaluate factors which govern the efficiency of antibody prophylaxis. Antibodies prepared in mice, rabbits, or man were 29 1

Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B.

“…concentrations ofantibody have been shown to protect against viral challenge when low doses ofvirus were used (18)(19)(20)(21)(22)(23). Our data with low dose viral challenge (Table II) confirms that antibody alone can be protective in high concentration, and protection was generally associated with neutralization activity.…”

Recombinant Interleukin-1?, Interleukin-2 and M-CSF-1 enhance the survival of newborn C57BL/6 mice inoculated intraperitoneally with a lethal dose of herpes simplex virus-1

“…The murine model reveals that newborn mice also have poor antibody responses to exogenous antigens [22]. However, administration of large doses of anti-HSV-1 antibodies immediately before or after infection with HSV-1 may alter the result of the infection [1,3,8,26,34]. Other immunologic defects previously described in newborn mice include defective macrophage function and impaired T-cell function, characterized by altered lym-84 C. Berkowitz and Y. Becker phokine production [14,17].…”